Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis

Nanfang Hospital, Southern Medical University

Status

Enrolling

Conditions

Decompensated Cirrhosis

Treatments

Dietary Supplement: Isomaltooligosaccharides (IMO)

Study type

Interventional

Funder types

Other

Identifiers

NCT06134544

NFEC-2023-457

Details and patient eligibility

About

The goal of this intervention clinical trial is to learn about the protection of isomaltooligosaccharides (IMO) on intestinal bacterial translocation in patients with liver cirrhosis. The main question is to answer the changes of LPS after adminstration of IMO.

Enrollment

18 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age from 18-75.
Cirrhotic patients.
Decompensation event: ascites.
LPS>0.45EU/ml.

Exclusion criteria

Pregnant or breast-feeding.
Active bacterial or fungal infection.
Other decompensations: Hepatic encephalopathy, gastroesophageal varices and hemorrhage.
Diagnosis of EASL-ACLF.
Diarrhea.
Malignancy.
Anticipated short survival time.
Adverse reactions or allergies to oral carbohydrate preparations.
Substance abuse or addiction.
Severe extrahepatic diseases (e.g. patients with CKD-5 stage, severe cardiopulmonary dysfunction, and psychiatric disorders).
Be immunosuppressed or immunodeficient states and the use of immunoglobulins or other immune-boosting conditions.
Be unsuitable for participating in this trial.
Participated in any drug trial within the past month
History of antibacterial or fungal use within 1 week prior to screening